Document Information


PMID 18414597  (  )
Title Altered Lipid Metabolism in Brain Injury and Disorders.
Abstract Deregulated lipid metabolism may be of particular importance for CNS injuries and disorders, as this organ has the highest lipid concentration next to adipose tissue. Atherosclerosis (a risk factor for ischemic stroke) results from accumulation of LDL-derived lipids in the arterial wall. Pro-inflammatory cytokines (TNF-alpha and IL-1), secretory phospholipase A(2) IIA and lipoprotein-PLA(2) are implicated in vascular inflammation. These inflammatory responses promote atherosclerotic plaques, formation and release of the blood clot that can induce ischemic stroke. TNF-alpha and IL-1 alter lipid metabolism and stimulate production of eicosanoids, ceramide, and reactive oxygen species that potentiate CNS injuries and certain neurological disorders. Cholesterol is an important regulator of lipid organization and the precursor for neurosteroid biosynthesis. Low levels of neurosteroids were related to poor outcome in many brain pathologies. Apolipoprotein E is the principal cholesterol carrier protein in the brain, and the gene encoding the variant Apolipoprotein E4 is a significant risk factor for Alzheimer's disease. Parkinson's disease is to some degree caused by lipid peroxidation due to phospholipases activation. Niemann-Pick diseases A and B are due to acidic sphingomyelinase deficiency, resulting in sphingomyelin accumulation, while Niemann-Pick disease C is due to mutations in either the NPC1 or NPC2 genes, resulting in defective cholesterol transport and cholesterol accumulation. Multiple sclerosis is an autoimmune inflammatory demyelinating condition of the CNS. Inhibiting phospholipase A(2) attenuated the onset and progression of experimental autoimmune encephalomyelitis. The endocannabinoid system is hypoactive in Huntington's disease. Ethyl-eicosapetaenoate showed promise in clinical trials. Amyotrophic lateral sclerosis causes loss of motorneurons. Cyclooxygenase-2 inhibition reduced spinal neurodegeneration in amyotrophic lateral sclerosis transgenic mice. Eicosapentaenoic acid supplementation provided improvement in schizophrenia patients, while the combination of (eicosapentaenoic acid + docosahexaenoic acid) provided benefit in bipolar disorders. The ketogenic diet where >90% of calories are derived from fat is an effective treatment for epilepsy. Understanding cytokine-induced changes in lipid metabolism will promote novel concepts and steer towards bench-to-bedside transition for therapies. Medicine and Public Health, Madison, WI.

NOTE: Color highlight is limited to the abstract and SciMiner text-mining mode. If you see much more identified targets below from "Targets by SciMiner Summary" and "Targets by SciMiner Full list", they may have been identified from the full text.



Targets by SciMiner Summary

HUGO ID Symbol Target Name #Occur ActualStr
11892TNFtumor necrosis factor (TNF superfamily, member 2)4TNF-alpha | tnf alpha |
5992IL1Binterleukin 1, beta4IL-1 | il 1 |
7897NPC1Niemann-Pick disease, type C12NPC1 | niemann pick disease |
14537NPC2Niemann-Pick disease, type C21NPC2 |
613APOEapolipoprotein E1apolipoprotein e |

 


Targets by SciMiner Full list

HUGO ID Symbol Name ActualStr Score FlankingText
11892TNFtumor necrosis factor (TNF superfamily, member 2)TNF-alpha1.5Pro-inflammatory cytokines (TNF-alpha TNF-alpha and IL-1 secretory phospholipase A(2) A 2 IIA and lipoprotein-PLA(2)
5992IL1Binterleukin 1, betaIL-11.0Pro-inflammatory cytokines (TNF-alpha TNF-alpha and IL-1 secretory phospholipase A(2) A 2 IIA and lipoprotein-PLA(2) lipoprotein-PLA 2
11892TNFtumor necrosis factor (TNF superfamily, member 2)TNF-alpha1.5TNF-alpha and IL-1 alter lipid metabolism and stimulate production of eicosanoids
5992IL1Binterleukin 1, betaIL-11.0TNF-alpha and IL-1 alter lipid metabolism and stimulate production of eicosanoids ceramide and
7897NPC1Niemann-Pick disease, type C1NPC10.9Niemann-Pick disease C is due to mutations in either the NPC1 or NPC2 genes resulting in defective cholesterol transport and cholesterol
14537NPC2Niemann-Pick disease, type C2NPC21.4C is due to mutations in either the NPC1 or NPC2 genes resulting in defective cholesterol transport and cholesterol accumulation
5992IL1Binterleukin 1, betail 11.0pro inflammatory cytokines tnf alpha and il 1 secretory phospholipase a 2 iia and lipoprotein pla 2 are implicated in vascular inflammation.
11892TNFtumor necrosis factor (TNF superfamily, member 2)tnf alpha1.0pro inflammatory cytokines tnf alpha and il 1 secretory phospholipase a 2 iia and lipoprotein pla 2 are implicated in vascular inflammation.
5992IL1Binterleukin 1, betail 11.0tnf alpha and il 1 alter lipid metabolism and stimulate production of eicosanoids ceramide and reactive oxygen species that potentiate cns injuries and certain neurological disorders.
11892TNFtumor necrosis factor (TNF superfamily, member 2)tnf alpha1.0tnf alpha and il 1 alter lipid metabolism and stimulate production of eicosanoids ceramide and reactive oxygen species that potentiate cns injuries and certain neurological disorders.
613APOEapolipoprotein Eapolipoprotein e1.0apolipoprotein e is the principal cholesterol carrier protein in the brain and the gene encoding the variant apolipoprotein e4 is a significant risk factor for alzheimer's disease.
7897NPC1Niemann-Pick disease, type C1niemann pick disease1.0niemann pick diseases a and b are due to acidic sphingomyelinase deficiency resulting in sphingomyelin accumulation while niemann pick disease c is due to mutations in either the npc1 or npc2 genes resulting in defective cholesterol transport and cholesterol accumulation.